Annual Securities Report — FY2025
What Tokuyama Corporation reported for the period from 2025-04-01 to 2026-03-31.
Filed 2026-06-19View the original on EDINET
How much it says
55Typical
What moved here
19named for the first time
Its own wording
77terms
Which filing this is
30/ 30newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
In the fiscal year ended March 2026, Tokuyama’s net sales and operating income increased, mainly because sales of semiconductor-related products remained firm. At the same time, the company recorded accounting impacts related to Tokuyama Life Science, which became a consolidated subsidiary through the acquisition of JSR-01, as well as an allowance for losses on a power supply contract.
Komori's summary of this document, not the document's own words.55Typical
How much this filing saysA weighted roll-up of 12 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 39 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
76
Very detailed
77
Very detailed
68
Detailed
62
Detailed
0
Almost nothing
45
Typical
0
Almost nothing
27
Almost nothing
100
Very detailed
69
Detailed
79
Very detailed
50
Typical
R&D spend0百万円Money spent making new things.
Cash left over-0百万円Cash from the business, less what went into equipment.
Spent on equipment0百万円Plants, machines — things meant to last.
Employees2,652Headcount at the end of this period.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.